{
  "docId": "019de074-71be-772a-8bed-f9d5eaece76b",
  "docSlug": "e4f10758c80bf7a23f09bd201ccd4281",
  "documentTitle": "Alkermes | Investor Presentation Deck | 32 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 32,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "other",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "Includes a molecular visualization of the Orexin 2 receptor.",
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de074-71be-772a-8bed-f9d5eaece76b/18",
  "deckHref": "/decks/019de074-71be-772a-8bed-f9d5eaece76b",
  "deckJsonHref": "/decks/019de074-71be-772a-8bed-f9d5eaece76b.json",
  "deckAnchorHref": "/decks/019de074-71be-772a-8bed-f9d5eaece76b#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.05,
        "y": 0.89
      },
      "kind": "disclaimer",
      "text": "PK: pharmacokinetic; PD: pharmacodynamic",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11f03871-131d-4f88-834d-c56609226c21",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.33,
        "x": 0.625,
        "y": 0.238
      },
      "kind": "image",
      "text": "Orexin 2 Receptor in Complex with Peptide-Agonist Orexin-B",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e87a8e78-964d-46b8-b2d7-7db28ae15353",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.5,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "list",
      "text": "Capture performance of endogenous peptide OX2R agonist; Increased wakefulness duration; Improved cataplexy control. Optimize potency and minimize predicted human dose to mitigate risk of undesired side effects. Provide PK/PD profile that mirrors natural wake cycle; Dose to allow for 8-12 hours wakefulness without subsequent insomnia. Enable convenient once-daily, oral medication.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8b2cf0db-d38b-4110-9e12-14c7220ac7ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "ALKS 2680 molecular design objectives:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1be3322d-3e0c-4c94-8d79-61513a7dee00",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.63,
        "y": 0.87
      },
      "kind": "source-note",
      "text": "Figure adapted from: Hong, Chuan, et al. Nature communications. 2021:12; 3. PDB ID: 7L1U",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "68576959-8592-4287-95f8-1cf7a948f015",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Leveraging Alkermes' Molecular Design Capabilities to Target Orexin Dysfunction",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f675e94e-ba4d-40c1-a8ac-f97d0111a086",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 8,
      "beatId": "94c87527-871a-454f-af4f-75bda8022c1a",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "LYBALVI prescription growth trends, ALKS 2680 clinical development plan",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 17,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "187a0d0b-46a7-4879-95f2-d6fe134e2cb5",
      "evidence": "Orexin Dysfunction: Well Defined Opportunity in Narcolepsy and Other Sleep Disorders",
      "position": 1,
      "objective": "why addressing orexin dysfunction is important",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}